Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: Case report

Benjamin T. Himes, Michael W. Ruff, Jaimie J. Van Gompel, Sean S. Park, Evanthia Galanis, Timothy J. Kaufmann, Joon H. Uhm

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


The authors present the case of a man with a papillary craniopharyngioma, first diagnosed at 47 years of age, who experienced multiple recurrences. Review of the pathologic specimen from his first resection demonstrated the BRAF V600E mutation. With his most recent recurrence following previous surgery and radiotherapy, at 52 years of age, the decision was made to initiate treatment with the BRAF V600E inhibitor dabrafenib. Imaging following initiation of dabrafenib demonstrated reduction in tumor size. He remained on dabrafenib therapy for approximately 1 year and continued to demonstrate a good clinical result. At that time the decision was made to discontinue dabrafenib therapy and follow up with serial imaging. After more than 1 year of follow-up since stopping dabrafenib, the patient has continued to do well with no radiographic evidence of tumor progression and continues to be monitored with frequent interval imaging.

Original languageEnglish (US)
Pages (from-to)1299-1303
Number of pages5
JournalJournal of neurosurgery
Issue number4
StatePublished - Apr 2019
Externally publishedYes


  • BRAF V600E
  • Craniopharyngioma
  • Dabrafenib
  • Oncology
  • Papillary

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology


Dive into the research topics of 'Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: Case report'. Together they form a unique fingerprint.

Cite this